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Immune dysfunction and abnormal immune response may be associated with certain 
mechanisms underlying autism spectrum disorder (ASD). The early evidence for this 
link was based on the increased incidence of ASD in children with a history of maternal 
infection during pregnancy. Observational studies show increased prevalence of 
immune-related disorders—ranging from atopy, food allergy, viral infections, asthma, 
primary immunodeficiency, to autoimmune disorders—in individuals with ASD and their 
families. Evidence of neuroglial activation and focal brain inflammation in individuals with 
ASD implies that the central nervous system immunity may also be atypical in some 
individuals with ASD. Also, both peripheral and central inflammatory responses are 
suggested to be associated with ASD-related behavioral symptoms. Atypical immune 
responses may be evident in specific ASD subgroups, such as those with significant 
gastrointestinal symptoms. The present review aimed to evaluate current literature of 
potential interventions that target inflammatory pathways for individuals with ASD and 
to summarize whether these interventions were associated with improvement in autism 
symptoms and adaptation. We found that the current literature on the efficacy of anti-
inflammatory interventions in ASD is still limited and large-scale randomized controlled 
trials are needed to provide robust evidence. We concluded that the role of immune-
mediated mechanisms in the emergence of ASD or related challenges may be specific to 
subsets of individuals (e.g. those with concurrent immunological disorders, developmental 
regression, or high irritability). These subsets of individuals of ASD might be more likely 
to benefit from interventions that target immune-mediated mechanisms and with whom 
next-stage immune-mediated clinical trials could be conducted.
Keywords: autism, inflammation, neuroinflammation, autism spectrum disorder, immune system
INTRODUCTION
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by early onset 
social-communication challenges, repetitive, stereotypical behaviors, and idiosyncratic sensory 
responsivity (1). Although several genetic and environmental factors have been linked to ASD, the 
underlying pathophysiology is still not well-understood (2). To date, although there have been great 
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progress in developing behavioral and psychological support for 
individuals with ASD, no approved medication therapy exist for 
the core symptoms; established medication treatment aims at 
reducing concurrent challenges, such as increased irritability (3). 
Considering the heterogeneous nature of this condition and the 
paucity of biomarkers, development of a safe and effective “one-
size-fits-all” medical therapy is challenging.
Several lines of evidence suggest a role of inflammation 
in the underlying developmental mechanisms of ASD (4–6). 
Epidemiological studies show an association between maternal 
infection [such as influenza (7) or cytomegalovirus (8)] during 
pregnancy and increased risk of offspring autism (9, 10). Also, 
family history of autoimmune diseases is associated with higher 
rate of ASD (11). In the animal models of ASD, offspring of 
animals with infection during pregnancy present physiological 
and behavioral alterations resemble ASD symptoms in human 
(12,13). People with ASD are suggested to have altered levels of 
inflammatory markers in which pro-inflammatory markers tend 
to increase while anti-inflammatory markers decrease (14, 15). 
Furthermore, postmortem studies of inflammation in the brain 
suggest alterations of brain immune response in ASD, including 
increased levels of proinflammatory markers (16) and increased 
microglial activation (17–19). Suzuki and colleagues showed 
increased microglial activation in the brain of individuals with 
ASD (20). Also, multiple studies on CSF and plasma/serum 
samples of individuals with ASD reported increased levels of 
proinflammatory markers (4, 21–23). Genetic studies reveal 
association between genomic variations in the immune-related 
genes and ASD (24). For example, human leucocyte antigen 
(HLA) DRB1 alleles are suggested to be associated with a 
higher risk of autism (25, 26). There is an emerging consensus 
that a better understanding of inflammation and its relation 
with the underlying pathophysiology of autism can provide 
new insight into the underlying mechanisms of the challenges 
faced by at least a subgroup of people with ASD (27), and help 
with developing new treatments. Given the current evidence, a 
growing body of literature has examined the role of medications 
with anti-inflammatory effects in the treatment of ASD-
associated challenges, either alone or as an adjuvant therapy. In 
this narrative review, we aimed to summarize studies exploring 
the use of medications that target inflammatory pathways for 
people with ASD and evaluate the effectiveness and side effect 
profiles. Both medications with primary anti-inflammatory 
action (e.g. celecoxib) and those with additional anti-
inflammatory properties beside their primary mechanisms of 
action (e.g. minocycline) have been included. These medications 
were selected based on the previous evidence indicating their 
anti-inflammatory properties in other psychiatric or medical 
disorders. Due to the availability of up-to-date meta-analysis on 
some of these agents, such as polyunsaturated fatty acids (28–31), 
they were not included in this review.
MeTHODS
This narrative review aimed to summarize the available evidence 
on the role of anti-inflammatory medications in the management 
of challenges associated with ASD. The literature search was 
performed using PubMed in July 2018. No publication date 
restriction was applied. We only included peer-reviewed studies 
on human subjects (with no age limitation) that were published 
in English language. The following search terms were used: 
(autism OR autistic OR autism spectrum disorder OR ASD OR 
pervasive OR pervasive developmental disorder OR pervasive 
developmental disorders OR Asperger OR Asperger’s) AND 
(celecoxib OR minocycline OR NAC OR N-acetylcysteine OR 
ACTH OR prednisone OR prednisolone OR hydrocortisone 
OR methylprednisolone OR dexamethasone OR cortisone OR 
triamcinolone OR betamethasone OR flavonoid OR lenalidomide 
OR pentoxifylline OR pioglitazone OR IVIG OR spironolactone 
OR topiramate OR memantine OR amantadine OR galantamine 
OR riluzole  OR palmitoylethanolamide). We also identified 
additional articles by reference list/hand searching.
STUDIeS OF MeDICATIONS TARGeTING 
INFLAMMATORY PATHWAYS IN PeOPLe 
WITH ASD (IN ALPHABeTICAL ORDeR)
Amantadine
Amantadine is an antiviral and anti-Parkinson medication that 
is widely used in the management of central nervous system 
disorders including multiple sclerosis (32) and traumatic brain 
injury (33). This medication is shown to be neuroprotective by 
the following mechanisms: (1) anti-inflammatory properties, 
mainly by inhibiting the release of proinflammatory factors 
(34, 35); (2) increasing the level of neurotrophic factors; 
and (3) inhibiting effect on N-methyl-D-aspartate (NMDA) 
receptors (34). In a placebo-controlled trial, King and colleagues 
studied the efficacy of amantadine in the management of ASD 
(36). They administered amantadine (n = 19) or placebo (n = 
20) to individuals with ASD (age range of 5–19 years) over 4 
weeks. The efficacy was measured using the Aberrant Behavior 
Checklist (ABC) and the Clinical Global Impression (CGI) 
scales. Amantadine group had slightly higher percentage of 
responders (equal or more than 25% reduction in irritability 
and/or hyperactivity according to parent-rated ABC). Based on 
the clinician-rated ABC, the amantadine group had significantly 
more improvement in absolute scores of hyperactivity and 
inappropriate speech. Also, amantadine group had higher 
improvement according to their CGI score. The side effects 
did not significantly differ between the amantadine and 
placebo groups.
Mohammadi and colleagues in a randomized controlled 
trial on children with severe behavioral issues (i.e. disruptive 
symptoms such as irritability) related to autism (age range of 
4–12 years), compared risperidone plus amantadine (n = 20) 
with risperidone plus placebo (n = 19) over a 10-week period 
(37). They observed a significant improvement in hyperactivity 
and irritability as measured by ABC in the amantadine group 
as compared to placebo. Also, the amantadine group had 
significantly more improvement than the placebo group based 
on the CGI scores. Side effects were not significantly different 
between the groups.
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Celecoxib
Celecoxib is a nonsteroidal anti-inflammatory drug that 
selectively inhibits cyclooxygenase-2 (COX-2) enzyme. It has 
been widely studied as an adjuvant therapy in several psychiatric 
disorders including schizophrenia and depression (38, 39). In a 
randomized and double-blind controlled trial, Asadabadi and 
colleagues investigated the effect of celecoxib as an adjuvant 
therapy to risperidone in the treatment of children (age range of 
4–12 years) with ASD and severe behavioral issues over 10 weeks. 
They used ABC rating scale to assess the clinical symptoms (40) 
(Table 1). Autistic children under treatment with celecoxib as an 
adjuvant therapy (n = 20) had significantly improved scores in 
irritability, social withdrawal/lethargy, and stereotypic behavior 
compared to the placebo group (n = 20). The study groups did 
not differ in terms of inappropriate speech, hyperactivity/non-
compliance, or medications side effects.
Corticosteroids and ACTH
Corticosteroids have been effectively used in the management of 
neurological disorders, such as Landau–Kleffner syndrome (LKS) 
(41). Due to similarities in the progression and development 
between LKS and regressive ASD, and considering the growing 
evidence on the link between inflammation and ASD, a number 
of studies have investigated the effects of corticosteroids or 
adrenocorticotrophic hormone (ACTH) in regressive ASD (42). 
In a series of trials, Buitelaar and colleagues studied the role of 
ORG 2766, an ACTH analog, in the management of children 
with ASD (43–45). In the first trial, they enrolled 14 children 
(age range of 5–13 years) with ASD in a double-blind crossover 
study (45). ORG 2766 was administered over a 4-week period. 
They reported significant improvement in clinical symptoms (i.e. 
irritability, stereotypic behaviors, hyperactivity, and excessive 
speech) as measured by the parent-reported ABC and playroom 
data. In the second crossover trial, they reported positive effects 
of ORG 2766 (administered over an 8-week period) on symptoms 
of 20 children (age range of 5–15 years) with ASD as measured by 
ABC and CGI (43). In their third study, they reported the effect 
of ORG 2766 on social interactions of autistic children enrolled 
in their first trial (44). They found that ORG 2766 therapy 
resulted in a significant increase in the quality and quantity of 
social interactions in the participants.
In a single-case study, Stefanatos and colleagues administered 
corticosteroid (i.e. prednisone) to a 6-year-old boy with 
regressive ASD over a 28-month period (46). The patient started 
losing his language abilities at age 22 months. The medical and 
neurological assessments were mostly unremarkable except 
for hypoperfusion of perisylvian cortical region in SPECT and 
abnormal steady-state auditory evoked potentials. Corticosteroid 
therapy resulted in significant improvement in language, social 
abilities, and stereotypic behaviors.
More recently, Shenoy and colleagues reported a case of 
regressive ASD that was diagnosed at the age of 18 months (47). 
He presented with progressive lymphadenopathy, microcytic 
anemia, mild thrombocytopenia, and low white blood cells count. 
He was started on corticosteroid at the age of 33 months. After 
about a month of steroid therapy, the patient started regaining 
his language and communication abilities. After 26 months of 
therapy, all the laboratory values returned back to normal.
Matarazzo described two cases of regressive ASD with 
histories of recurrent bacterial infections (48). Both individuals 
were initially started on corticosteroid therapy and later due 
to the side effects, were switched to ACTH. In both cases, 
corticosteroid therapy led to improvement in language and 
communication skills, as well as behavioral symptoms, such as 
stereotypic behaviors.
Mordekar and colleagues reported two cases of regressive 
ASD treated with corticosteroid (49). The first case was a 
4.5-year-old boy with ASD and generalized tonic–clonic 
seizure that regained his personality and language abilities after 
treatment with corticosteroid. The second case was a 4-year-
old girl with ASD who lost her language and communication 
abilities after experiencing neurological symptoms associated 
with ataxia and fluctuation of consciousness. Her symptoms 
started to improve after three weeks of treatment with 
prednisolone. Forty-eight months after treatment, she was back 
to her normal function and personality.
Most recently, a retrospective study (age range of participants, 
3–5 years) compared 20 children with regressive ASD treated 
with corticosteroids (for a maximum period of 4 months) 
with 24 autistic children without corticosteroid treatment; the 
authors observed significant improvement in the frequency 
modulated auditory evoked response, language function, 
and ASD symptom score according to DSM-IV criteria after 
corticosteroid therapy (50).
Taken together, there is a lack of randomized controlled trials 
to inform the clinical utility of corticosteroid in individuals 
with ASD. Single case, case series, and observational studies 
indicate the potential of corticosteroid or ACTH as a treatment 
for regressive ASD, but this awaits rigorous controlled trials to 
validate and to investigate the potential underlying mechanisms 
of action.
Flavonoids
Flavonoids are a large group of nutrients found in vegetables and 
fruits. They are shown to have anti-inflammatory effects through 
inhibition of inflammatory pathways, including the synthesis/
activity of c-reactive protein, proinflammatory cytokines, 
and microglia (51). Theoharides and colleagues studied the 
effects of a flavonoids mixture (luteolin, quercetin, and rutin) 
in an open-label case-series of 37 children (age range of 4–14 
years) with ASD over a period of 4 months (52). They reported 
improvement in attention and eye contact (50%), allergy and 
gastrointestinal symptoms (75%), and social interaction (25%). 
No side effects due to the treatment were noted. More recently, 
using similar supplement, Taliou and colleagues in an open-label 
trial studied 40 children (age range of 4–10 years) with ASD over 
a 26-week period (53). They reported significant improvement in 
communication, daily living skills, and social skills as measured 
by the Vineland Adaptive Behavior Scales (VABS) and also in 
hyperactivity, irritability, lethargy, and stereotypical behavior as 
measured by the ABC. More recently, the same group using the 
same database reported that children with ASD that had the most 







TABLe 1 | Summary of the studies on the role of anti-inflammatory medications in the management of ASD.




Amantadine ASD (DSM-IV and 
ICD-10)  
N = 39  
Age: 5–19 years
Double-Blind, Placebo-
Controlled Trial Amantadine 
(n = 19), Placebo (n = 20)
Amantadine administered at 2.5 mg/kg/
day for 1 week and then 5 mg/kg/day 
for 3 weeks.
Based on parent-rated ABC amantadine group 
had slightly higher (statistically non-significant) 
percentage of responders. However, based on 
the clinician-rated ABC, the amantadine group 
had significantly more improvement in absolute 
score of hyperactivity and inappropriate 
speech than placebo group. 
- Amantadine group had higher CGI score (not 
statistically significant) than placebo group.







(6 or more DSM 
IV-TR symptoms)  
N = 39, Age: 4–12 
years
Double-Blind, Placebo-
Controlled Trial Risperidone 
plus Amantadine (n = 20) 
Risperidone plus placebo 
(n = 19)
Risperidone administered between 
1 and 2.0 mg/day, Amantadine 
administered at 100 mg/d (if <30 kg) or 
150 mg/d (if >30 kg), over 10 weeks
-Significant improvement in hyperactivity and 
irritability in the amantadine treated than the 
placebo group. 
- Significant improvement in the amantadine 
group on CGI





Children with ASD 
((DSM)-IV-TR) 




controlled trial Risperidone 
plus Celecoxib (n = 20), 
Risperidone plus placebo 
(n = 20)
Celecoxib:100 mg/day to 200/300 
mg/day Risperidone: 0.5 mg/day to 
0.5 mg/week to 2–3 mg/day over 10 
weeks
Significant improvement in: 
- Irritability -Lethargy/Social Withdrawal 
- Stereotypic Behavior as measured with ABC








A 6-year-old boy 
with autoimmune 
condition plus ASD
Case study 2 mg/kg/day for 10 weeks followed 
by 0.5 mg/kg every other day for 12 
months 
2 mg/kg of daily for 4 weeks, measured 
monthly by 0.5 mg/kg from weeks 4 
through 12. Between weeks 12 to 28, 
alternate-day dosing was quantified in 
0.25 mg/kg steps every 4 weeks.
Significantly improved: 
-Spontaneous speech, greater responsiveness 
to verbal communications (Token Test for 
Children), and improved social relatedness. 
-Receptive (Peabody Picture Vocabulary Test) 
and expressive Vocabulary 
-Visuomotor abilities and Performance 
IQ(WISC-R) -Decreased Stereotyped 
utterances (Diagnostic Checklist for Behavior-
Disturbed Children)










Age: 18 months old
Case study 2 mg/kg/day for 10 weeks. the 
prednisolone dose was further reduced 
to 0.4 mg/kg every other day. Finally, 
the dose of 0.5 mg/kg every other day 
was the effective maintenance dose for 
treatment of the ASD and autoimmune 
condition
- Increased social interaction 
- Improvements in speech, gesturing, 
non-verbal communication, and language 
expression and comprehension subjective 
improvement, followed by objective 
improvement in speech and developmental 
milestones
Shenoy et al., 2000 
(47)
(Continued)
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TABLe 1 | Continued
Drug Participants Type of study Treatment Outcomes References Benefit based 
on strength 
of evidence
Steroid Children with 
regressive Autism 
Spectrum Disorder 







(N = 25), Age: 3–5 
years
Retrospective Study Oral prednisolone administered at 2 
mg/kg/day. Treatment group: 4 Hz 
frequency modulated evoked response 
(FMAER) derived from language cortex 
of the superior temporal gyrus (STG)
-Significant increase in the 4 Hz FMAER 
spectral response and a significant reduction in 
response distortion compared to STAR group 
relative to the NSA group. 
- Significant improvement in STAR group 
subjects’ language ratings 
- Most STAR group children showed significant 
behavioral improvement after treatment. 
-STAR group language and behavior 
improvement were retained one year after 
treatment. 
- Groups did not differ in terms of minor EEG 
abnormalities. -Steroid treatment produced no 
lasting morbidity.
Duffy et al., 2014 
(50)
Case 1: 4.5-year-old 




tonic clonic seizure 
Case 2: 4.5-year-
old girl with CDD 
who was mildly 
encephalopathic
Case series Case 1: Prednisolone (40 mg; 2 mg/kg/
day for 2 weeks and then weaned by 5 
mg a week over 8 weeks). Prednisolone 
(2 mg/kg for 2 weeks, tapered over 
1 week
-Remained seizure free on Sodium Valproate 
(30 mg/kg/day) and at 2-year follow-up his 
behavior remained normal. 
-Normal academic school progress at 30 
months follow-up. 
-Slow improvement with fewer periods of 
agitation in the next 3 weeks 
-Clear understanding of some verbal 
commands and developed a little speech.
- No periods of agitation or ataxia,
Mordekar et al., 
2009 (49)
Adrenocorticotropic hormone (ACTH)
ORG 2766 ASD  




20 mg/day over 4 weeks period Significant Improvement in irritability, 
stereotypic behaviors, hyperactivity, and 
excessive speech) as measured with ABC








20 mg/day over 8 weeks period - Significant Improvement in stereotypic 
behaviors 
- Social interaction-, play behavior, and 
stereotypy 
(P < 0.05 for each) compared with placebo 
(ABC and CGI); 
-Adverse effects were minimal
Buitelaar et al., 
1992 (44)
ORG 2766 ASD,  
N = 20  
Age: 5–15 years
Controlled trial 40 mg/day for 8 weeks -Significant improvement in the children’s play 
behavior and a significant increase in the social 
interaction between child and experimenter. 
-Gaze coordination between child and 
experimenter
—Parents’ checklist ratings (ABC) as well as 
clinicians’ ratings (CGI).
Buitelaar et al., 
1992 (43)
(Continued)
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TABLe 1 | Continued
Drug Participants Type of study Treatment Outcomes References Benefit based 
on strength 
of evidence
ACTH Case 1: 8-year-old 
boy with ASD Case 
2: 2-year-old girl with 
ASD
Case studies Case 1: prednisone l0 mg/day followed 
by ACTH 10 IU/day 
Case 2: 10 mg of prednisone plus 
ampicillin as prophylactic treatment 
daily for two months which was 
replaced by ACTH 10 IU i.m. daily
-He was attentive and had no more echolalia, 
or stereotypies, 
-He was able to communicate using simple 
phrases, and to perform simple tasks; to 
correctly use toys and was willing to play with 
other children 
-Improvement in pronouncing a few words, 
understanding demands, 
-Improved attentiveness, calmness, and less 
isolatedness.
Matarazzo et al., 
2002 (48)
Flavonoids
Children with ASD 
N = 37,  
Age: 4–14 years, 29 
boys and 8 girls
Case studies -luteolin (100 mg) + quercetin (70 mg) + 
Flavonoid (200 mg)  
−2 capsules/20 kg/weight, or at least 
400 mg total flavonoid
-Significant improvement in bowel color, form 
and habits in 2–3 weeks (75%) 
-Significant reduction in Allergic-like symptoms 
in their skin 
-Significant improvement in eye contact, and 
attention to directions (50%) 
-Significant improvement in retained learned 
tasks and social interactions (30–50% of patients) 
-Significant improvement in speaking skills (10%)




ASD children N = 40, 
Age: 4–10 years; 42 
boys and 8 girls
Prospective, open-label trial 
Two age groups: 4–6 years 
(n = 25), 7–10 years (n = 25)
luteolin (100 mg/capsule, from 
chamomile) and quercetin (70 mg/
capsule), and the quercetin glycoside 
rutin (30 mg/capsule) for 26 weeks
-Significant improvement in adaptive 
functioning as measured by Vineland Adaptive 
Behavior Scale (VABS) age-equivalent 
scores in the communication domain, 
daily living skills, and the social domain 
-Significant improvement in overall behavior 
as demonstrated by the decline in ABC 
subscale scores. 
-Age had no significant effect on results
Taliou et al., 2013 
(53)
10-year-old boy Case study Co-Ultramicronized 
Palmitoylethanolamide/ Luteolin: 700 
mg + 70 mg for 1 year
-Significantly decrease both total and subgroup 
scores, in particular; sociability, demonstrating 
improved behavioral outcome, in particular 
sociability (as per ATEC) 
-Significantly reduced most indexes of 
hyperactivity, as shown by reduction in motor 
stereotypies 
-Improved cognition as reported by parents 
and teachers (e.g. understanding of simple 
commands and accomplishing them easily; 
-Improved eye contact and the child’s behavior 
became more affectionate
Bertolino et al., 
2017 (55)
(Continued)
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TABLe 1 | Continued





IV-TR) Case 1: 
21-year-old male
Case 2: a 32-year-
old male
Case 3: 42-year-old 
male
Case series Case 1: Initial dose of 4 mg each 
month to a maximum of 12 mg as 
an adjunct treatment to his asthma 
medications
Case 2: 4 mg daily Galantamine 
followed by a trial of donepezil due to 
side effects
Case 3: Initial does of 4 mg per day for 
a month to a maximum of 16 mg
Case 1: Improved speech and cognition: active 
speech sound production 
-Spontaneous articulation, proper to the 
context and complex verbalizations 
Case 2: -Improvements in verbalizations, which 
were restricted to one- or two appropriate 
word responses to the questions asked 
Case 3: 
-Slight improvement in spontaneous speech 
and drooling 
-Significant improvement in aggressive 
behavior within the first month of treatment.




Children with autism 
N = 13, Mean Age: 
8.8 +/- 3.5 years
12- week Open-label trial -Significant improvement in irritability and social 
withdrawal subscales of ABC 
-Significant progresses in inattention and 
emotional liability (Conners’ Parent Rating 
Scale-R) -Improvement in the anger subscale 
of the Children’s Psychiatric Rating Scale.
Nicolson et al., 
2006 (58)
ASD (DSM IV-TR) 




blind trial Risperidone 
plus galantamine (n = 20) 
Risperidone plus placebo 
(n = 20)
Galantamine administered up to 24 
mg/day or placebo, plus Risperidone 
administered up to 2 mg/day, for 10 
weeks
-Significant improvement in the Irritability and 
Lethargy/Social Withdrawal subscales in the 
galantamine treated patients than the placebo 
group as measured with ABC





abnormalities N = 10, 
Age: 3–12 years
Open-label Study 400 mg/kg/month for 6 months at 4 
weeks intervals
-Improvements in speech (better articulation 
and improved vocabulary) 
-one child almost completely recovered speech 
-Improved social behavior, better eye contact, 
loss of echolalia, and response to commands. 
- Mild improvement on spontaneous 
meaningful speech









N = 10, -Age: 4–17 
years
Open-label study 4 infusions of (154 to 375 mg/kg), every 
6 weeks
Mild improvements in attention and 
hyperactivity (n = 4) 
-No improvements (n = 5) 
- Almost total amelioration of autistic 
symptoms (n = 1)
Piloplys et al., 1998 
(61)
(Continued)
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TABLe 1 | Continued
Drug Participants Type of study Treatment Outcomes References Benefit based 
on strength 
of evidence
ASD (DSM IV) N = 7 
-Age: 3–6 years (6 
male, 1 female),
Pilot Open Clinical Trial 400 mg/kg/month- for 6 months Not beneficial for behaviors or severity Delgiudice-Asch et 
al., 1999 (62)
Outpatient male 
children with autism 




0.4 g/kg at once Significant improvement in Irritability, 
hyperactivity, Inadequate eye contact, and 
Inappropriate speech as measured with ABC
Niederhofer et al., 
2003 (63)
ASD N = 26, Age: 
3–17 years
Open retrospective study 400 mg/kg/month IVIG for 6 months -Significant decrease in irritability, social 
withdrawal, stereotypy, hyper- activity, 
inappropriate speech as measured with ABC 
-Regressing to pre-IVIG level within 2 to 4 
months of termination of IVIG (n = 22)
Boris et al., 2005 
(64)
Children with ASD, 
N = 31
Open-label case series Initiated with 2 g/kg monthly with 1 g/
kg/day for 2 days monthly
Reports from parents:  
-Improvements in communication and/or 
language with fewer reporting  
-Improvements in aberrant behavior, repetitive 
behavior, and academics, social interactions, 
tics, motor function, and seizures  
-Significant Improvement in cognition and 
mannerisms on Social Responsiveness Scale, SRS) 
-Mild significant improvement in 
communication and motivation (SRS) 
-Significant improvement in irritability, 
lethargy/social withdrawal, hyperactivity, and 
inappropriate speech as measured with ABC




N = 7, Age: 6–12 
years
Open-label (Pilot Study) 2.5 mg/day for 12 weeks -Significant improvement in socialization, 
expressive, and receptive language (CGI) 
-Significant decreased symptoms of autism 
based on the CARS scores in six children who 
completed the 6-week follow-up





Children with ASD 
(DSM-IV-TR) N = 40, 
Age: 4–12 years
Double-blind, placebo-
controlled study Risperidone 
plus Memantine (n = 20) 
Risperidone plus placebo 
(n = 20)
Risperidone was administered up to 3 
mg/d and memantine was administered 
up to 20 mg/day Initiate Risperidone 
with dose of 0.5 mg with subsequent 
dose increase in 0.5 mg increments 
weekly Initiate Memantine with dose 
of 5 mg/day with subsequent dose 
increase in 5 mg increments weekly for 
10 weeks
Significant improvement in irritability, 
stereotypic behavior, and hyperactivity as 
measured with ABC
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TABLe 1 | Continued
Drug Participants Type of study Treatment Outcomes References Benefit based 
on strength 
of evidence
Autistic disorder, or 
Asperger disorder 
((DSM-IV-TR) plus 
Moderate to severe 
ASD based on Social 
Responsiveness 
Scale-Adult Research 
Version (SRS-A), and 
the clinician-rated 




Initiated with a daily dose of 5 mg that 
was increased by 5 mg weekly up to 
a maximum daily dose of 20 mg twice 
daily. (average dose, 19.7 ± 1.2 mg/day; 
range, 15–20 mg)
-Significant improvement in the severity of core 
features of autism based on (SRS) and (CGI)  
-Significant improvement in impaired reading 
and nonverbal communication based on 
Diagnostic Analysis of Nonverbal Accuracy 
Scale test and in executive function per self-
report (Behavior Rating Inventory of Executive 
Functioning–Adult Self-Report Global Executive) 
-Significant improvement in cognitive dysfunction 
in particular executive areas of emotional control, 
task initiation, cognitive flexibility, self-regulation, 
planning and organization, response inhibition, 
and working memory;  
-Significant improvement in global functioning 
-Significant improvement in anxiety and ADHD 
symptoms






and the Autism 
Diagnostic Interview-
Revised (ADI-R) 
N = 121, Age: 6–12 
years Study 2: ASD 
(DSM-IV-TR) N = 66 
(completed the study) 
Age: 5–16 years
Study 1: 12- week, 
randomized, double-blind, 
placebo-controlled, parallel-
group. Placebo (n = 61), 
Memantine (n = 60). Study 
2: 48-week open-label 
extension trial (enrolled 
participants n = 102; n = 66, 




Memantine doses were administered 
based on bodyweight and ranged 
between 3 and 15 mg/day
Study 1:  
-No significant between-group difference 
on the efficacy outcome of caregiver/parent 
ratings based on the Social Responsiveness 
Scale (SRS),  
-A Significant improvement as compared to 
baseline at Week 12 in both groups  
Study 2:  
-A tendency for improvement at the end of the 
extension period (48 weeks).  
-No significant improvements in the active 
group  
- Significant worsening of one communication 
measure in memantine group relative to 
placebo after 12 weeks.





- Revised (ADI-R)), 
DSM-IV, or the 
Autism Diagnostic 
Observation 
Schedule N = 10 
Age: 3–12 years
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Risperidone plus minocycline 
(n = 23), Risperidone plus 
placebo (n = 23)
50 mg twice per day for 10 weeks plus 
Risperidone titrated up to 2 mg/day
-Significant improvement of irritability and 
hyperactivity/noncompliance
Ghaleiha et al., 
2016 (74)
N-acetylcysteine
Children with ASD 
(DSM-IV-TR),  




NAC (n = 14) Placebo 
(n = 15)
Initiated with 900 mg/daily for 4 weeks, 
followed by 900 mg/twice daily for 4 
weeks and then 900 mg/three times 
daily for 4 weeks
-Significant reduction in irritability in the 
treatment group as measured with ABC 
-Significant improvement on stereotypies as 
measured with RBS-R  
- Significant improvements in social cognition 
and autism mannerisms as measured with SRS




8-year-old boy with 
ASD (DSM-IV)
Case study 800 mg per day over 6 weeks - Significant reduction in his nail-biting behavior 
- Significant reduction in his autistic symptoms 
1 month after the onset of treatment  
-Significant improvement in: social interaction 
( visual analog scale), verbal skills and 
communication (visual analog scale), 
aggressive behavior, hyperactivity and limited 
interests, and severity and frequency of his 
blinking tic (parents report)





N = 40, Age: 3.5–16 
years
Randomized double blind 
placebo controlled trial NAC 
plus Risperidone (n = 17) 
Placebo plus Risperidone 
(n = 14)
1200 mg/day NAC + Risperidone or 
placebo + Risperidone for 8 weeks
Significant improvement in irritability as 
measured with ABC
Ghanizadeh et al., 
2013 (81)
4-year-old boy with 
self-injurious behavior
Case study Initiated with 0.45 g/d and titrated up to 
1.8 g/day over 3 weeks
Improvement in frequency and severity of self-
injurious behavior
Marler et al., 2014 
(77)
17 years old 
with ASD
Case study Administered 20% acetylcysteine oral 
solution started at 600 mg twice daily 
as an add-on to Quetiapine therapy for 
six weeks. continued acetylcysteine 
with 900 mg twice a day plus 
Quetiapine 200 mg twice a day
Significantly improved tantrums, irritability, and 
aggressive behavior
Stutzman et al., 
2015 (79)
Children with autism 
spectrum disorder 
(ASD) N = 40, Age: 
4–12 years
A Randomized, Double-Blind, 
Placebo-Controlled Clinical 
Trial Risperidone plus NAC 
(n = 20) Risperidone plus 
placebo (n = 20)
Risperidone administered up to 1 and 
2.0 mg/d, NAC dosage was 600 to 900 
mg/day over 10 weeks
-Significant interaction of time and treatment 
on irritability, and hyperactivity/ Noncompliance 
subscales.  
-By the end of trial, the treatment group 
had more improvement in irritability and 
hyperactivity/ noncompliance subscales scores 
as measured with ABC
Nikoo et al., 2015 
(82)
(Continued)
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Asperger’ s disorder, 
PDD NOS, ASD 
((DSM-IV, (ADI-R))) 
N = 31, Age: 4–12 
years
Randomized, double-blind, 
placebo-controlled trial NAC 
(n = 16), Placebo (n = 15)
Regular daily dose was 56.2 mg/
kg over week 12, with dose varying 
between 33.6 - 64.3 mg/kg. Initiated 
with the dose of 300 mg/day for 
weights between 15 to 30 kg Initiated 
with the dose of 600 mg/day, > 30 kg
- No significant difference between the 
treatment and placebo groups on the CGI test
Wink et al., 2016 
(83)
Children with ASD 
(DSM-IV-TR) N = 98, 
Age: 3–9 years
Placebo-controlled, 
randomized clinical trial NAC 
(n = 48) Placebo (n = 50)
500 mg/day orally administered over 
6 months
-No significant differences between treatment 
and placebo-treated groups for, scores on the 
SRS, Children’s Communication Checklist and 
the RBS  
-No significant difference found on the three 
global impression scales: DBC-P, CGI, and 
PGI-I
Dean et al., 2017 
(84)
Palmitoylethanolamide
Case 1: 13-year-old 
male with autism 
Case 2: 15-year-old 
male with autism
Case series Case 1: Oral administration of 1/2 
tablet (300 mg) twice daily, followed by 
(600 mg) tablet twice daily for a month 
Case 2: 600 mg tablet for 3 months
Case 1: -Improvement in his behavior and 
expressive language (parents and school 
teacher’s reports)  
-Decrease in tantrums, outburst, self-talking, 
and stereotypies. -Improvement in skin 
eczema, nose-picking, asthmatic cough, and 
allergy stigmata  
Case 2: -Improvement in speech, sociability, 
sensory/cognitive, and overall behaviour 
-Improvement in aggression and cognitive and 
behavioral skills, and Language





(DSM-V) N = 62, 
Age: 4–12 years
Randomized, parallel group, 
double-blind placebo-
controlled trial Risperidone 
plus PEA (n = 31), Risperidone 
plus placebo group (n = 31)
Children in both groups received 
Risperidone equally with initial dose of 
0.5 mg and stepwise 0.5-mg weekly 
increases for the first 3 weeks plus 600 
mg PEA twice daily over 10 weeks
-Significant improvement on ABC irritability 
and hyperactivity/noncompliance, and 
inappropriate speech symptoms related to 
risperidone plus placebo group




of biological basis or 
autism N = 36, Age: 
3–15 years
Open-label study 150–600 mg/day over 1 month -Remarkably effective in (N = 10) Fairly effective 
in (N = 8) Slightly effective in (N = 3) No effect 
(N = 2)  
-Improvement in sameness maintenance 
syndrome as well as in increasing the 
understanding of language and human 
relations and in their self-image to the extent 
(based on authors observations)




ASD N = 30 Case 
reports: aged 12, 13, 
and 15 years
Open-label study Not specified -Marked improvement (n = 6) -Slight 
amelioration of symptoms (n = 14) -three out of 
six patients reported marked improvement
Nakane et al., 1980 
(91)
Male autistics N = 20, 
Age: 3–22 years
Open-label study 200 mg/day for 3 months –35% improvement in behavior and mental 
development
Shimoide et al., 
1981 (92)
(Continued)
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Drug Participants Type of study Treatment Outcomes References Benefit based 
on strength 
of evidence
Psychotic (N = 18) 
and autistic children 
(N = 2): a 5-year-old 
boy and a 7-year-old 
girl
Open-label study Dose of 50 mg/day to 200 mg/day 
Over 4–10 months
-Significant improvement in pronunciation of 
syllables and words  
-Significant improvements in behavior and in 
language  
-Significant Increased in attention to others 
and speech 
-Improvement in pronunciation of syllables and 
words
Turek et al., 1981 
(93)
ASD (based on 




Risperidone plus pentoxifylline 
(n = 20), risperidone plus 
placebo (n = 20)
Pentoxifylline: 200- 600 mg/day 
Risperidone: 0.5- 3 mg/day Over 
10 weeks
Significant improvement in:  
-Irritability, social withdrawal, and stereotypic 
behavior 
-Hyperactivity and inappropriate speech As 
measured with ABC
Akhondzadeh et al., 
2010 (94)
Pioglitazone
ASD (DSM-IV) N = 25, 
Age: 3 –17 years
Open-label study 30 mg/day for individuals with age 
range of 3 to 5 years 60 mg/day for 
individuals with age range of 6–17 
years -Over 4 months
-Significant decrease in hyperactivity, Irritability, 
lethargy, and stereotypy as measured with ABC




Outpatients with ASD 




controlled trial Risperidone 
plus Pioglitazone (n = 20) 
Risperidone plus placebo 
(n = 20)
Risperidone: initial dose of 0.5 mg/
day which was titrated in 0.5 mg 
increments every week over 10 weeks 
Pioglitazone: dose of 30 mg/day (15 
mg two times daily) in one group
-Significant reduction in irritability, lethargy/
social withdrawal and hyperactivity/
non-compliance




N = 40, Age: 5–12 
years
Double-Blind, Placebo-
Controlled, Randomized Trial 
Risperidone plus Riluzole (n = 
20), Risperidone plus placebo 
(n = 20)
Riluzole administered up to 50 or 100 
mg/day according to bodyweight. 
Risperidone administered up to 2 or 3 
mg/day (according to bodyweight) for 
10 weeks.
-Significant improvement in the irritability, 
lethargy/social withdrawal, stereotypic 
behavior, and hyperactivity/non-compliance 
subscale in Riluzole-treated patients - 11 
individuals in Riluzole group and 5 individuals 
in the placebo group were categorized as 
responders according to their CGI scores










Case Report 2 mg/kg/day for 4 weeks -Significant improvement in irritability, social 
withdrawal, stereotypy, hyperactivity, inappropriate 
speech as measured with ABC 
-Significant improvement in receptive language 
(as measured with Peabody Picture Vocabulary 
Test III)






(DSM IV), N = 40, 
Age: 3–12 years
Double-blind, placebo-
controlled trial Risperidone 
plus Topiramate (n = 20) 
Risperidone plus placebo 
(n = 20)
Risperidone was administered up to 2 
mg/d for children between 10 and 40 kg 
and 3 mg/day for >40 kg. Topiramate 
was administered up to 100 mg/day for 
individuals <30 kg and 200 mg/day for 
individuals >30 kg) over 8 weeks
Significant improvement on irritability, 
stereotypic behavior, and hyperactivity/non-
compliance subscales as measured with ABC
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behavioral improvement were the ones that had reduction in the 
serum levels of IL-6 and TNF following treatment with luteolin 
(54). Most recently, Bertolino and colleagues reported a single case 
of a 10-year-old boy with regressive ASD and history of recurrent 
febrile seizure who underwent treatment with a flavonoid 
supplement (Palmitoylethanolamide/Luteolin) over a 12-month 
period (55). Treatment with the flavonoid supplement led to 
improvement in ASD symptoms as measured by ASD treatment 
evaluation checklist (ATEC) and a scale for stereotypic behavior 
and the frequency of enuresis. No side effects were reported.
Overall, there may be a potential for the use of flavonoid in 
the management of individuals with ASD that need to be further 
examined in robust clinical trials. Due to insufficient evidence, 
no clinical recommendations can be made so far with regard to 
the use of flavonoids.
Galantamine
Galantamine is an acetylcholinesterase inhibitor approved 
for the treatment of Alzheimer’s disease. It also has anti-
inflammatory properties by inhibiting the pro-inflammatory 
markers, such as TNF and cytokines (56). Hertzman studied 
the effect of galantamine on three adults with autism (57). 
The first patient was a 21-year-old male. Treatment with 4 
mg of galantamine for a month led to improvement in verbal 
communication and the patient started making sound and 
responding. The second case was a 32-year-old male that after 
treatment with 4 mg of galantamine presented with improvement 
in verbalization; however, he experienced allergic reactions and 
the medication was discontinued. The third case was a 42-year-
old male. He presented aggressive behaviors and never had verbal 
communication. Treatment with 4 mg of galantamine within a 
month led to reduction of aggressive behaviors. In a more recent 
study, Nicolson and colleagues studied galantamine effects in an 
open-label trial on 13 children (mean age, 8.8 ± 3.5 years) with 
autism over a 12-week period (58). Children presented significant 
improvement in irritability and social withdrawal as measured by 
ABC and emotional liability and attention as measured by Conners’ 
parent-rating scale. Moreover, children presented improvement 
in aggression as measured by the children’s psychiatric rating 
scale. Except for headache in one child, galantamine treatment 
was well tolerated. In the only randomized controlled trial 
available, Ghaleiha and colleagues compared risperidone plus 
galantamine (n = 20) with risperidone plus placebo (n = 20) over 
a 10-week period in children (age range of 4–12 years) with ASD 
(59). They observed a significant improvement in irritability and 
lethargy/social withdrawal subscales of ABC with galantamine 
as compared to placebo. The side effects were not significantly 
different between the groups. These initial findings indicate the 
potential to further evaluate the benefit and safety of galantamine 
for autistic individuals in robust clinical trials.
Intravenous Immunoglobulin
Several open-label trials have investigated intravenous 
immunoglobulin (IVIG) therapy in ASD, particularly those 
with concomitant immunological deficits. Gupta and colleagues 
administered IVIG to 10 children (age range of 3–6 years) with 
ASD and IgG deficiency and/or high levels of maternal rubella 
antibody at 4 weeks interval for a minimum period of 6 months 
(60). Behavior, cognition, and developmental characteristics of 
these children were evaluated using Peabody picture vocabulary 
test, the VBAS, skill evaluation, and preschool language test. 
Treatment with IVIG resulted in improvement in social behavior, 
eye contact, echolalia, response to commands, and speech.
Later, Plioplys and colleagues studied IVIG administration in 
10 children (age range of 4–17 years) with ASD and immunologic 
abnormalities (61). The IVIG infusions were administered every 
6 weeks. Six children received four infusions and one individual 
each received 1, 3, 5, and 6 infusions. While five individuals did 
not experience any changes in their symptoms, four children were 
reported by their parents to have mild improvement in attention 
and hyperactivity. One individual had a significant improvement 
in social behavior and language in a step-wise fashion after each 
infusion. However, the clinical improvement reversed 2 months 
after the last (6th) infusion, and he again presented with the same 
severe autistic symptoms as he presented before participating in 
the study.
DelGiudice-Asch and colleagues administered IVIG to seven 
children (age range of 3.5–6 years) with ASD without known 
immunological anomalies at monthly intervals over a 6-month 
period (62). Five children received the six infusions and finished 
the study. Overall there were no significant improvement in any 
of the clinical symptoms as measured by Ritvo-Freeman Real 
Life rating scale, the children Yale-Brown Obsessive-Compulsive 
Scale, CGI scale for autistic disorder, and the ASD modification 
of the NIMH global obsessive-compulsive scale.
In a double-blind, placebo-controlled crossover study, 
Niederhofer and colleagues studied the effects of a single dose 
of IVIG on clinical symptoms of 12 children (age range of 4.2–
14.9 years) with ASD as measured by ABC (63). The participants 
were medication free and had no immunological disorders. They 
found a significant improvement in parent-reported irritability, 
hyperactivity, inadequate eye contact, and inappropriate speech 
as measured by ABC and drowsiness and decreased activity 
as measured by the symptom checklist. However, none of the 
clinician ratings showed significant differences between placebo 
and IVIG groups. No remarkable side effects were noted.
In an open-label study, Boris and colleagues administered 
IVIG to 26 children (age range of 3–17 years) with ASD (with 
history of developmental regression) at a monthly basis for 
6 months (64). They observed a significant improvement in 
total aberrant score (37%), hyperactivity (39%), inappropriate 
speech (25%), irritability (42%), lethargy (35%), and stereotypic 
behavior (28%) on the ABC. Only a small number of the 
participants experienced side effects. However, most children’s 
behavior returned to their pre‐IVIG status within 2–4 months of 
discontinuing the IVIG.
In an open-label case-series study, Connery and colleagues 
administered IVIG to 31 children (mean age of 9 years and 9 
months with standard deviation of 4 years and 5 months) with 
ASD and autoimmune encephalopathy on a monthly basis (65). 
Clinical outcomes were measured using ABC and the Social 
Responsiveness Scale (SRS) as completed by the caretakers. IVIG 
treatment resulted in significant improvement in cognition and 
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mannerism sub-scales and the total score of SRS. Moreover, 
they reported a significant improvement in irritability, lethargy, 
hyperactivity, and speech sub-scores as well as the total score of 
ABC. The most common side effects were headache and vomiting, 
which were common but limited to the infusion period.
Taken together, current evidence suggests potential benefit 
of IVIG in children with ASD and concomitant immunological 
disorders, such as autoimmune encephalopathy; however, given 
the common side effects and the invasiveness of the intervention, 
IVIG treatment needs to be considered cautiously, weighing 
the risks and benefits. More robust clinical trials in large cohort 
are required to further establish the evidence. For children 
with ASD without known immunological deficits, current 
evidence is inconsistent and insufficient, and therefore, there is 
no clear rationale so far to recommend IVIG treatment for this 
subpopulation of ASD.
Lenalidomide
Lenalidomide, a derivative of thalidomide, is an 
immunomodulatory medication widely used in the treatment 
of hematologic disorders and malignancies (66). In an open-
label study, Chez and colleagues administered lenalidomide to 
seven male children aged 6 to 12 years with ASD and history of 
developmental regression and elevated levels of TNF-alpha, for a 
12-week period (67). They observed a significant improvement 
in ASD symptoms as measured by the Childhood Autism Rating 
Scale (CARS) and also in expressive language as measured 
by CGI. Moreover, although not significant, treatment with 
lenalidomide decreased the levels of TNF-alpha in both serum 
and CSF. However, it is important to note that among the seven 
children enrolled, two developed a rash and discontinued the 
study, and an additional one discontinued from the study after 
eight weeks due to transient drop of absolute neutrophil count 
to <1500.
Memantine
Memantine is an NMDA receptor blocker with suggested 
neuroprotective and anti-inflammatory effects (68). Ghaleiha and 
colleagues in a randomized controlled trial compared treatment 
with memantine plus risperidone (n = 20) with risperidone plus 
placebo (n = 20) in children (age range of 4–12 years) with ASD 
(69). They reported significant improvements in irritability, 
stereotypic behavior, and hyperactivity/non-compliance as 
measured by ABC in the memantine group compared to the 
placebo group. They did not find any significant difference in the 
side effects between groups. More recently, an open-label study 
evaluated the efficacy and tolerability of memantine on 18 adults 
(age range of 18–50 years) with autism over a 12-week period 
(70). Treatment with memantine was associated with significant 
improvement in autism severity as measured by the SRS, CGI, 
MGH ASD rating scale, and brief psychiatric rating scale as 
well as anxiety, ADHD symptoms, nonverbal communication 
(measured by Diagnostic Analysis of Nonverbal Accuracy Scale 
test) and in executive function (measured by the Behavioral 
Rating Inventory of Executive Functioning and Cambridge 
neuropsychological test automated battery). Treatment with 
memantine was not associated with any serious adverse event. 
Most recently, in the largest randomized controlled trials so far 
on the efficacy of memantine in children (age range of 6–12 years) 
with autism, Aman and colleagues compared treatment with 
memantine (n = 60) with placebo (n = 61) over a 12-week period 
(71). They did not observe any significant clinical improvement 
as measured by the SRS, although in the 48-week open-label 
follow up, a trend of improvement was observed. They reported 
two serious adverse events during the study that both were 
recognized to be unrelated to the treatment.
Taken together, the current evidence does not support a role 
for memantine in the treatment of core autism characteristics 
and associated challenges. It is notable that some large-scale 
randomized controlled trials are still ongoing (e.g. https://
clinicaltrials.gov/ct2/show/NCT01972074).
Minocycline
Minocycline is a tetracycline-class antibiotic with anti-
inflammatory effects (72). In an open-label trial, Pardo and 
colleagues investigated the effect of minocycline on clinical 
measures (as measured by CGI and VABS) and blood/
cerebrospinal fluid (CSF) growth factors and markers of 
inflammation in autistic children (age range of 3–12 years) with 
history of regression (n = 10) over a 6-month period (73). While 
minocycline did not have a significant effect on core autism 
symptoms and adaptive functioning, it significantly reduced IL-8, 
an anti-inflammatory cytokine, and brain-derived neurotrophic 
factor (BDNF) in the CSF, and BDNF level (as normalized by 
alpha-2 macroglobulin level) in serum. In contrast to BDNF, 
hepatic growth factor (HGF) in the CSF significantly increased 
after treatment with minocycline.
In a randomized placebo-controlled trial, Ghaleiha and 
colleagues evaluated the effect of minocycline as an adjunctive 
therapy to risperidone in autistic children over a 10-week period 
(74). Minocycline significantly improved scores on irritability 
and hyperactivity/noncompliance on the ABC; however, it did 
not have any significant effect on lethargy/social withdrawal, 
stereotypic behavior, and inappropriate speech. The authors 
did not report any significant difference in side effects between 
groups. The observed difference in the effects of minocycline 
on clinical presentations of the participants in the above studies 
might be due to the difference in the administered dosage, 1.4 
mg/kg/day in the Pardo et al. study (73) versus 100 mg/day in the 
Ghaleiha et al. study (74).
Taken together, there is still insufficient evidence to support 
the use of minocycline in the treatment of core autism symptoms 
or associated challenges.
N-Acetylcysteine
There is a growing interest in the potential use of N-acetylcysteine 
(NAC) in the treatment of psychiatric disorders (75). NAC acts 
as a precursor for glutathione, the most abundant antioxidant 
in the brain and is shown to have both anti-oxidant and anti-
inflammatory properties in the body (76). Several case reports and 
trials have investigated the effect of NAC in individuals with ASD.
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In a case study, Marler and colleagues administered NAC to a 
4-year-old autistic child with self-injurious behavior over a 3-week 
period and observed improvement in frequency and severity of 
self-injurious behavior (77). In another case study, Ghanizadeh 
and Derakhshan examined NAC effects on clinical symptoms 
of an 8-year-old boy with ASD over a 6-week period (78). They 
observed significant improvement in social impairment, social 
interaction, nail-biting behavior, verbal skills and communication, 
tics, and aggression as measured with visual analog scale by the 
parents. Stutzman and Dophiede studied a 17-year-old boy with 
ASD and intellectual disability who was treated with NAC as an 
adjuvant therapy to quetiapine over 6 weeks (79). Treatment with 
NAC led to a reduction in irritability and aggressive behaviors.
Several small-scale clinical trials suggest a potentially 
positive role for NAC. Hardan and colleagues in a 12-week 
randomized controlled trial treated children (age range of 3.2–
10.7 years) with ASD with NAC (n = 14) or placebo (n = 15) 
(80). They observed a significant improvement in irritability 
(as measured by the ABC) and a trend toward significance 
on stereotypic/repetitive behaviors (as measured by ABC and 
Repetitive Behavior Scale-Revised) in the NAC compared to 
the placebo group. Additionally, NAC significantly improved 
mannerism score (as measured by the SRS). Groups did not 
significantly differ in terms of medication side effects. In a more 
recent randomized controlled trial, Ghanizadeh and colleague 
observed a significant improvement in irritability score (as 
measured by ABC), but not the core autism symptoms, in 
children (age range of 3.5–16 years) with ASD treated with 
risperidone and NAC (n = 17) as compared to risperidone 
and placebo (n = 14) over an 8-week period (81). In this trial, 
the most commonly reported side effects were constipation, 
increased appetite, fatigue, nervousness, and daytime 
drowsiness. In a similar study, Nikoo and colleagues compared 
autistic children (age range of 4–12 years) under treatment 
with risperidone and NAC (n = 20) with those treated with 
risperidone and placebo (n = 20) over a 10-week period (82). 
They observed a significant improvement in irritability and 
hyperactivity/noncompliance as measured by the ABC. No 
significant differences in side effects were found between 
the groups. Wink and colleagues in a 12-week randomized 
controlled trial compared autistic children (age range of 4–12 
years) on NAC (n = 16) versus placebo (n = 15) (6 patients 
were later excluded due to adverse effects or losing follow up) 
in terms of their social impairment as measured by CGI scale, 
and also oxidative stress markers in the blood (83). They did 
not find any significant difference between groups with regard 
to their CGI, ABC, SRS, or VABS-II scores. However, they 
observed a significant increase in the level of glutathione and 
a trend toward significance for increase in the level of oxidized 
glutathione (GSSG) in the NAC group.
Dean and colleagues in a randomized controlled trial 
compared treatment with NAC versus placebo in 98 children (age 
range of 3.1–9.9 years) with ASD (50 in the placebo group, 48 in 
the NAC group) (84) and observed no significant effect of NAC 
on their primary (i.e. SRS, RBS-R, and children’s communication 
checklist (CCC-2)) or secondary (i.e. CGI or developmental 
behavior checklist) outcomes. There was no significant difference 
in the frequency or severity of adverse events between groups.
Overall, although initial small-scale clinical trials show the 
potential of NAC in reducing irritability in children with ASD (and 
possibly some aspects of autistic characteristics in the repetitiveness 
domain), follow-up larger-scale trials so far fail to show impact on 
ASD core characteristics. Considering the relatively safe side effect 
profile, NAC may have a positive role in the treatment of irritability 
in autistic children (85), but so far there is no evidence supporting 
its use in targeting ASD core symptoms.
Palmitoylethanolamide
Palmitoylethanolamide is a fatty acid amide with neuroprotective, 
anti-inflammatory, and anti-nociceptive properties that exert its 
effect through the peroxisome proliferator-activated receptors 
(PPAR)-dependent pathway (86). In a case report, Antonucci 
and colleagues studied efficacy of palmitoylethanolamide on 
two adolescents with autism. The first was a 13-year-old male 
with regressive autism and history of eczema and allergy. After 
treatment with palmitoylethanolamide (Normast®; initially 600 
mg daily and then 1200 mg daily) for 1 month, they observed 
a significant improvement in the CARS-2 score, behavior 
(i.e. tantrums, stereotyped behaviors, self-talking, outbursts), 
language abilities, and allergic symptoms (87). The second child 
was a 15-year-old male with a history of epilepsy. Treatment with 
Normast for three months led to significant improvement in 
ATEC score, aggression, cognition, and behavioral skills as well 
as blood IgE levels. In a randomized controlled trial, Khalaj and 
colleagues compared risperidone plus palmitoylethanolamide 
versus risperidone plus placebo over a 10-week period in 
children (age range of 4–12 years) with ASD (88). Treatment with 
palmitoylethanolamide resulted in significant improvement in 
ABC irritability and hyperactivity/noncompliance compared to 
placebo. The groups did not differ with regard to the side effects.
Taken together, more randomized controlled trials are needed 
to evaluate the use of palmitoylethanolamide in the treatment of 
core autism characteristics or associated challenges, as current 
evidence is still too limited to support its clinical use.
Pentoxifylline
Pentoxifylline is a xanthine derivative which has an inhibitory 
effect on inflammatory responses in the body (e.g. by interfering 
with TNF-alpha effect) (89). In an early open-label trial, Sogame 
administered pentoxifylline to 36 children (age range of 3–15 
years) with ASD or behavioral disorders with organic etiology 
(90). He observed improvement in maintenance of sameness, 
language, and relation with others in the majority of the 
participants. He observed side effects, such as nausea, vomiting, 
headache, and low blood pressure in a small number of the 
participants. Nakane reported results of an open-label study 
of pentoxifylline on 30 children with ASD (91). Children were 
also on haloperidol. The assessment was based on the parents’ 
observation. While six children had significant improvement of 
symptoms, 14 children presented minor improvements. Shimoide 
administered pentoxifylline to 20 male individuals (age range 
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of 3–22 years) with ASD over a 3-month period and observed 
improvement in at least two of their three assessments (i.e. 
patients’ behavior in specific situations, mental developmental 
scale for young children, Seiken’s critical list for autistic children) 
(92). Side effects were related to gastrointestinal symptoms. 
Turek studied the effects of pentoxifylline on 2 children (a 
5-year-old boy and a 7-year-old girl) with ASD and 18 with 
psychosis (93). He observed significant improvement in syllables 
and words pronunciation of the autistic children. Observed side 
effects were limited to excitement and sleep disturbances. In the 
only randomized controlled trial, Akhondzadeh and colleagues 
compared treatment with risperidone plus pentoxifylline 
(n = 20) versus risperidone plus placebo (n = 20) (94). Treatment 
with pentoxifylline led to a significant improvement on ABC 
in irritability, lethargy/social withdrawal, stereotypic behavior, 
hyperactivity/noncompliance, and inappropriate speech. Side 
effects were not significantly different between groups.
Taken together, pentoxifylline may be a beneficial adjuvant 
therapy for ASD when combined with risperidone, but the 
evidence is still insufficient, and robust clinical trials are needed.
Pioglitazone
Pioglitazone is an antidiabetic medication of the thiazolidinedione 
class that is commonly used for reducing blood glucose in patients 
with type 2 diabetes mellitus. It exerts its effect mainly through 
the peroxisome proliferator-activated receptors (PPAR) pathway. 
Due to the anti-inflammatory properties of this medication, it 
is suggested to be potentially beneficial in the management of 
psychiatric disorders (95–97). In an open-label trial, Boris and 
colleagues administered pioglitazone to 25 children (age range of 
3–17 years) with ASD over a 3- to 4-month period and observed 
a significant improvement in irritability, lethargy, stereotypy 
behaviors, and hyperactivity as measured by the ABC (98). 
Improvements in irritability, lethargy, and hyperactivity were 
significantly associated with age, suggesting younger participants 
may benefit more from pioglitazone than older children. No 
significant side effects were observed among the participants.
Most recently, a 10-week randomized controlled trial 
compared the efficacy of risperidone plus pioglitazone (n = 
20) versus risperidone plus placebo (n = 20) (99). This study 
found a significant improvement in ABC irritability, lethargy/
social withdrawal, and hyperactivity/non-compliance after 
treatment with pioglitazone as compared to placebo. There was 
no significant difference in the side effects (mostly vomiting and 
headache) between pioglitazone and placebo groups.
Collectively, initial findings suggest a potential beneficial 
role for pioglitazone in the management of ASD in children, yet 
robust clinical trials are needed to provide adequate evidence.
Riluzole
Riluzole is known as the only beneficial medication for increasing 
survival in patients with amyotrophic lateral sclerosis (ALS). 
It mainly exerts its effect by inhibiting presynaptic release of 
glutamate. It is also shown to have anti-inflammatory effects (100). 
In a randomized controlled trial, Ghaleiha and colleagues (110)
compared risperidone plus riluzole (n = 20) versus risperidone 
plus placebo (n = 20) over a 10-week period in children (age range 
of 5–12 years) with ASD. They observed significant improvement 
in ABC irritability, lethargy/social withdrawal, stereotypic 
behavior, and hyperactivity/noncompliance. Regarding the side 
effects, the riluzole group had significantly higher increase in 
appetite and weight gain. It is noteworthy that a large phase 2 trial 
studying riluzole effects on 58 participants has been conducted 
recently (https://clinicaltrials.gov/ct2/show/NCT01661855).
Spironolactone
Spironolactone as an antagonist for aldosterone receptor has 
a primary use in the management of condition associated 
with elevated levels of aldosterone. It is shown to have anti-
inflammatory properties, potentially due to its affinity for other 
steroid receptors (101, 102). In a single case report and hypothesis 
paper, Bradstreet and colleagues administered spironolactone to 
a 12-year-old child with ASD and elevated testosterone level, 
over a 4-week period and observed improvement in irritability 
(79%), lethargy (83%), stereotypic behavior (60%), hyperactivity 
(72%), and inappropriate speech (67%) as measured by the ABC 
(103). They also noted improvement in receptive language.
Topiramate
Topiramate is an anti-epilepsy medication which is known to have 
neuroprotective effects (104), exerting through anti-inflammatory 
and antioxidant effects (105, 106). In the only study in autistic 
individuals, Rezaei and colleagues compared risperidone plus 
topiramate (n = 20) with risperidone plus placebo (n = 20) over 
an 8-week period in children (age range of 3–12 years) with ASD 
and observed a significant improvement in ABC irritability, 
stereotypic behavior, and hyperactivity/noncompliance (107). The 
topiramate group had significantly higher number of somnolence 
and decreased appetite than the placebo group.
Although initial evidence implies a potentially positive 
adjuvant role for topiramate, more robust clinical trials are 
required to determine whether the benefits are consistent and 
outweigh the side effects.
CONCLUSIONS AND FUTURe DIReCTION
While pharmacological interventions are frequently used in the 
management of concomitant psychiatric and behavior challenges 
in individuals with ASD, they have limited effect on the core 
symptoms of ASD. Current evidence on the role of inflammation 
in the underlying mechanisms leading to autism, or more 
importantly, to specific subgroups/subtypes of autism (e.g. those 
with concurrent immunological disorders) (27), has fueled the 
research on the potential use of agents with anti-inflammatory 
effects in the management of this condition (108) [as in a 
recent example of the treatment for a subgroup of individuals 
with depression (109)]. The literature on anti-inflammatory 
medications in the management of ASD is still in its infancy, 
dominated by case reports and open-label studies, with only a 
small portion of double-blind randomized controlled trials (in 
which many acted as adjuvant agents combined with risperidone) 
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for which the findings are often not replicated yet. Nevertheless, 
certain findings imply potential for future investigation with more 
robustly conducted trials, especially in ASD subgroups such as 
those with concurrent immunological disorders, developmental 
regression, or high irritability/behavioral challenges.
This literature implies potential benefits of the following 
medications for ASD children with severe behavioral 
challenges (alone or especially when acting as an adjuvant 
agent with risperidone): amantadine, celecoxib, galantamine, 
N-acetylcysteine, palmitoylethanolamide, pentoxifylline, 
pioglitazone, riluzole, and topiramate. A small number of case 
report and case-series studies suggests a potential role for 
corticosteroids and ACTH in the management of regressive 
autism. Flavonoids are suggested by a few open-label studies to 
be a safe medication to potentially improve behavioral symptoms 
such as irritability. IVIG might be beneficial in ASD individuals 
with concurrent immunological disorders. Lenalidomide 
appeared to be beneficial to ASD individuals with developmental 
regression and with elevated TNF-alpha. However, it is 
important to note that the current evidence for efficacy and 
safety of all these medications in individuals with ASD is still 
very preliminary and inconclusive. For clinical decision making, 
safety should be the primary concern. These medications 
should be considered only when 1) the medication is indicated 
for the co-occurring medical disorder (e.g. immunological 
disorders); or 2) standard treatments have been depleted or are 
insufficient, and the potential benefits are judged to outweigh 
potential harms [note: N-acetylcysteine has been recommended 
in the latest clinical care pathway for reducing irritability in 
autistic individuals (85)]. Current evidence on the role of anti-
inflammatory agents in ASD should be interpreted considering 
the following limitations. First, across all medications reviewed 
here, there is a lack of rigorous randomized double-blind 
placebo-controlled trials and very few successful replications 
so far. The available literature is enriched with case reports and 
open-label studies. There are a few randomized controlled trials, 
but they are often of small sample sizes and are being tested 
in the context of an adjuvant agent (i.e., with risperidone). 
Therefore, based on the studies that evaluate anti-inflammatory 
medications as adjuvant therapy, it is unclear whether the effect 
of an anti-inflammatory medication comes from the medication 
(or the anti-inflammatory action) itself. Secondly, most clinical 
trials have focused on short-term effects (about 12 weeks) of the 
medications. It can be difficult to detect significant changes in 
a short period of time, and the evidence for long-term efficacy 
or safety is still lacking. Finally, for most of the medications 
reviewed here, the exact mechanisms of action (including the 
biological link between their anti-inflammatory mechanisms 
and behavior changes of the individual) are not clear, so the 
interpretation of the findings is challenging, especially when 
there are other potentially non-immune-mediated mechanisms 
of action that may contribute to the neurobiological basis of 
ASD (e.g. the glutamatergic system).
In conclusion, current evidence supporting the efficacy and 
safety of anti-inflammatory interventions in ASD is still limited. 
Robust large-scale clinical trials are much needed. Nevertheless, 
some findings imply that the role for immune-mediated 
mechanisms in the emergence of autism or autism-related 
challenges may be specific to a subset of people with autism 
(27, 111). It may be the case that the greatest potential of anti-
inflammatory agents lies in this aspect, in the light of stratified 
psychiatry and precision medicine.
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